Search
Ethyl biscoumacetate
go.drugbank.com/drugs/DB08794ApprovedWithdrawnEthyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)
DP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure
Trifluoperazine
go.drugbank.com/drugs/DB00831ApprovedIt is used as an antipsychotic and an antiemetic.
Dexpramipexole
go.drugbank.com/drugs/DB15130InvestigationalFrom the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)). … Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured
Categories: Compounds used in a research, industrial, or household settingClobutinol
go.drugbank.com/drugs/DB09004ApprovedWithdrawnClobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.
Guanoxan
go.drugbank.com/drugs/DB13211ApprovedGuanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage. … Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.
DDP733
go.drugbank.com/drugs/DB05049InvestigationalSerotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. … DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD).
Norclozapine
go.drugbank.com/drugs/DB05766InvestigationalIt combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today. … ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.
Synonyms: N-DesmethylclozapineGirentuximab
go.drugbank.com/drugs/DB05304InvestigationalGirentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).